Warby Parker Inc. (WRBY)
USD 14.81
(2.99%)
USD 14.81
(2.99%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -42.43 Million USD | -20.54% |
| 2022 | -35.2 Million USD | 86.27% |
| 2021 | -256.41 Million USD | 18.36% |
| 2020 | -314.08 Million USD | -466.69% |
| 2019 | -55.42 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -38.93 Million USD | 8.25% |
| 2024 Q2 | -45.71 Million USD | -17.41% |
| 2023 FY | -42.43 Million USD | -20.54% |
| 2023 Q1 | -33.62 Million USD | 4.48% |
| 2023 Q2 | -42.31 Million USD | -25.81% |
| 2023 Q4 | -42.43 Million USD | 7.31% |
| 2023 Q3 | -45.78 Million USD | -8.21% |
| 2022 Q1 | -78.98 Million USD | 69.2% |
| 2022 FY | -35.2 Million USD | 86.27% |
| 2022 Q4 | -35.2 Million USD | -42.24% |
| 2022 Q3 | -24.75 Million USD | 53.41% |
| 2022 Q2 | -53.13 Million USD | 32.73% |
| 2021 Q3 | -266.23 Million USD | -2.13% |
| 2021 Q2 | -260.67 Million USD | -182.99% |
| 2021 Q1 | 314.08 Million USD | 200.0% |
| 2021 Q4 | -256.41 Million USD | 3.69% |
| 2021 FY | -256.41 Million USD | 18.36% |
| 2020 FY | -314.08 Million USD | -466.69% |
| 2020 Q4 | -314.08 Million USD | 0.0% |
| 2020 Q1 | 55.42 Million USD | 0.0% |
| 2019 FY | -55.42 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alcon Inc. | 4.04 Billion USD | 101.048% |
| AptarGroup, Inc. | 961.03 Million USD | 104.416% |
| Baxter International Inc. | 11.16 Billion USD | 100.38% |
| Becton, Dickinson and Company | 14.46 Billion USD | 100.293% |
| Bausch + Lomb Corporation | 4.23 Billion USD | 101.003% |
| Haemonetics Corporation | 695.08 Million USD | 106.105% |
| Envista Holdings Corp | 713.6 Million USD | 105.947% |
| ResMed Inc. | 635.57 Million USD | 106.677% |
| Teleflex Incorporated | 1.7 Billion USD | 102.491% |
| West Pharmaceutical Services, Inc. | -544.9 Million USD | 92.212% |